ERYTECH Pharma S.A. (0QSS.L)
ERYTECH Pharma S.A.
60 Avenue Rockefeller
Lyon 69008
France
33 4 78 74 44 38
https://www.erytech.com
Sector(s):
Industry:
Full-time employees: 149
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Gil Beyen BVBA | CEO & Director | 536.31k | N/A | 1962 |
| Mr. Eric Soyer Ph.D. | Deputy GM, CFO & COO | 365.41k | N/A | 1966 |
| Dr. Jérôme Bailly Pharm.D. | Deputy GM of Operations, Chief Quality Officer & Qualified Person | 224.92k | N/A | 1979 |
| Naomi Eichenbaum | Director Investor Relations | N/A | N/A | N/A |
| Mr. Brian Schwab | Chief Legal Officer & Gen. Counsel | N/A | N/A | 1965 |
| Ms. Anne-Cécile Fumey | HR Director | N/A | N/A | 1975 |
| Dr. Iman El-Hariry M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1960 |
| Dr. Philip L. Lorenzi | Consultant & Member of Scientific Board | N/A | N/A | N/A |
| Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board | N/A | N/A | N/A |
| Dr. Bridget Bax | Consultant & Member of Scientific Board | N/A | N/A | N/A |
Description
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Corporate governance
ERYTECH Pharma S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
